Association of genetic polymorphisms and autoimmune Addison’s disease

References

• Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison’s disease underestimated? J. Clin. Endocrinol. Metab.84, 1762 (1999).
   PubMed Web of Science ®Google Scholar
• Lovas K, Husebye ES. High prevalence and increasing incidence of Addison’s disease in western Norway. Clin. Endocrinol. (Oxf.)56, 787–791 (2002).
   PubMed Web of Science ®Google Scholar
• Oelkers W. Adrenal insufficiency. N. Engl. J. Med.335, 1206–1212 (1996).
   PubMed Web of Science ®Google Scholar
• Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev.23, 327–364 (2002).
   PubMed Web of Science ®Google Scholar
• Nomura K, Depura H, Saruta T. Addison’s disease in Japan: characteristics and changes revealed in a nationwide survey. Intern. Med.33, 602–606 (1994).
   PubMedGoogle Scholar
• Aubourg P. On the front of X-linked adrenoleukodystrophy. Neurochem. Res.24, 515–520 (1999).
   PubMed Web of Science ®Google Scholar
• McCabe ER. DAX1: increasing complexity in the roles of this novel nuclear receptor. Mol. Cell. Endocrinol.265–266, 179–182 (2007).
   Google Scholar
• Achermann JC, Ito M, Ito M, Hindmarsch PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat. Genet.22, 125–126 (1999).
   PubMed Web of Science ®Google Scholar
• Clark AJ, McLoughlin L, Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet341, 461–462 (1993).
   PubMed Web of Science ®Google Scholar
• Weber A, Wienker TF, Jung M et al. Linkage of the gene for the triple A syndrome to chromosome 12q13 near the type II keratin gene cluster. Hum. Mol. Genet.5, 2061–2066 (1996).
   PubMed Web of Science ®Google Scholar
• North K, Korson MS, Krawiecki N, Shoffner JM, Holm IA. Oxidative phosphorylation defect associated with primary adrenal insufficiency. J. Pediatrics128, 688–692 (1996).
   Google Scholar
• Andersson HC, Frentz J, Martínez JE, Tuck-Muller CM, Bellizaire J. Adrenal insufficiency in Smith–Lemli–Opitz syndrome. Am. J. Med. Genet.82, 382–384 (1999).
   PubMedGoogle Scholar
• Blizzard RM, Kyle MA. Studies of the adrenal antigens and antibodies in Addison’s disease. J. Clin. Invest.42, 1653–1660 (1963).
   PubMed Web of Science ®Google Scholar
• Sotsiou F, Bottazzo GF, Doniach D. Immunofluorescence studies on autoantibodies to steroid-producing cells and to germline cells in endocrine diseases and infertility. Clin. Exp. Immunol.39, 97–111 (1980).
   PubMed Web of Science ®Google Scholar
• Winqvist O, Karlsson FA, Kämpe O. 21-hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet339, 1559–1562 (1992).
   PubMed Web of Science ®Google Scholar
• Bednarek J, Furmaniak J, Wedlock N et al. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison’s disease. FEBS Lett.309, 51–55 (1992).
   PubMed Web of Science ®Google Scholar
• Furmaniak J, Kominami S, Asawa T, Wedlock N, Colls J, Smith BR. Autoimmune Addison’s disease-evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J. Clin. Endocrinol. Metab.79, 1517–1521 (1994).
   PubMed Web of Science ®Google Scholar
• Boscaro M, Betterle C, Volpato M et al. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. J. Clin. Endocrinol. Metab.81, 2801–2804 (1996).
   PubMed Web of Science ®Google Scholar
• Laureti S, Candeloro P, Aglietti MC et al. Dehydroepiandrosterone, 17α-hydroxyprogesterone and aldosterone responses to the low-dose (1 µg) ACTH test in subjects with preclinical adrenal autoimmunity. Clin. Endocrinol. (Oxf.)57, 677–683 (2002).
   PubMedGoogle Scholar
• Falorni A, Nikoshkov A, Laureti S et al. High diagnostic accuracy for idiopathic Addison’s disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J. Clin. Endocrinol. Metab.80, 2752–2755 (1995).
   PubMed Web of Science ®Google Scholar
• Colls J, Betterle C, Volpato M, Prentice L, Smith BR, Furmaniak J. Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin. Chem.41, 375–380 (1995).
   PubMed Web of Science ®Google Scholar
• Tanaka H, Perez MS, Powell M et al. Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. J. Clin. Endocrinol. Metab.82, 1440–1446 (1997).
   PubMed Web of Science ®Google Scholar
• Falorni A, Laureti S, Santeusanio F. Autoantibodies in autoimmune polyendocrine syndrome type II. Endocrinol. Metab. Clin. N. Am.31, 369–389 (2002).
   PubMed Web of Science ®Google Scholar
• Falorni A, Laureti S, Nikoshkov A et al. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison’s disease. Clin. Exper. Immunol.107, 341–345 (1997).
   PubMed Web of Science ®Google Scholar
• Laureti S, Aubourg P, Calcinaro F et al. Etiological diagnosis of primary adrenal insufficiency using an original flow-chart of immune and biochemical markers. J. Clin. Endocrinol. Metab.83, 3163–3168 (1998).
   PubMed Web of Science ®Google Scholar
• Falorni A, Laureti S, De Bellis A et al. Italian Addison Network Study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J. Clin. Endocrinol. Metab.89, 1598–1604 (2004).
   PubMed Web of Science ®Google Scholar
• da Carmo Silva R, Kater CE, Dib SA et al. Autoantibodies against recombinant human steroidogenic enzyme 21-hydroxylase, side-chain cleavage and 17α-hydroxylase in Addison’s disease and autoimmune polyendocrine syndrome type III. Eur. J. Endocrinol.142, 187–194 (2000).
   Google Scholar
• Laureti S, De Bellis A, Muccitelli VI et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with pre-clinical Addison’s disease. J. Clin. Endocrinol. Metab.83, 3507–3511 (1998).
   PubMedGoogle Scholar
• Betterle C, Volpato M, Rees Smith B et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. J. Clin. Endocrinol. Metab.82, 932–938 (1997).
   PubMedGoogle Scholar
• Coco G, Dal Pra C, Presotto F et al. Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies. J. Clin. Endocrinol. Metab.91, 1637–1645 (2006).
   PubMed Web of Science ®Google Scholar
• Falorni A, Laureti S. Adrenal autoimmunity and correlation with adrenal dysfunction. Endocrinologist10, 145–154 (2000).
   Google Scholar
• Laureti S, Arvat E, Di Vito L et al. Low (1 µg) dose ACTH test in the evaluation of adrenal dysfunction in preclinical Addison’s disease. Clin. Endocrinol. (Oxf.)53, 107–115 (2000).
   PubMed Web of Science ®Google Scholar
• The Finnish–German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet.17, 399–403 (1997).
   PubMed Web of Science ®Google Scholar
• Tuomi T, Björses P, Falorni A et al. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. J. Clin. Endocrinol. Metab.81, 1488–1494 (1996).
   PubMed Web of Science ®Google Scholar
• Betterle C, Greggio NA, Volpato M. Clinical review 93: autoimmune polyglandular syndrome type 1. J. Clin. Endocrinol. Metab.83, 1049–1055 (1998).
   PubMed Web of Science ®Google Scholar
• Halonen M, Eskelin P, Myhre AG et al.AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy– candidiasis–ectodermal dystrophy phenotype. J. Clin. Endocrinol. Metab.87, 2568–2574 (2002).
   PubMed Web of Science ®Google Scholar
• Robles DT, Fain PR, Eisenbarth GS. The genetics of autoimmune polyendocrine syndrome type II. Endocrinol. Metab. Clin. N. Am.31, 353–368 (2002).
   PubMed Web of Science ®Google Scholar
• Freeman M, Weetman AP. T and B cell reactivity to adrenal antigens in autoimmune Addison’s disease. Clin. Exp. Immunol.88, 275–279 (1992).
   PubMedGoogle Scholar
• Hayashi Y, Hiyoshi T, Takemura T, Kurashima C, Hirokawa K. Focal lymphocytic infiltration in the adrenal cortex of the elderly: immunohistological analysis of infiltrating lymphocytes. Clin. Exp. Immunol.77, 101–105 (1989).
   PubMedGoogle Scholar
• Nerup J, Andersen V, Bendixen G. Anti-adrenal, cellular hypersensitivity in Addison’s disease. Clin. Exp. Immunol.4, 355–363 (1969).
   PubMed Web of Science ®Google Scholar
• Nerup J, Andersen V, Bendixen G. Anti-adrenal, cellular hypersensitivity in Addison’s disease. IV. In vivo and in vitro investigations on the mitochondrial fraction. Clin. Exp. Immunol.6, 733–739 (1970).
   PubMedGoogle Scholar
• Rabinowe SL, Jackson RA, Dluhy RG, Williams GH. Ia-positive T lymphocytes in recently diagnosed idiopathic Addison’s disease. Am. J. Med.77, 597–601 (1984).
   PubMed Web of Science ®Google Scholar
• Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med.199, 1285–1291 (2004).
   PubMed Web of Science ®Google Scholar
• Husebye ES, Bratland E, Bredholt G, Fridkin M, Dayan M, Mozes E. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison’s disease, is an immunodminant T cell epitope. Endocrinology147, 2411–2416 (2006).
   PubMedGoogle Scholar
• Peterson P, Pitkänen J, Sillanpää N, Krohn K. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clin. Exp. Immunol.135, 348–357 (2004).
   PubMed Web of Science ®Google Scholar
• Pitkänen J, Vähämurto P, Krohn K et al. Subcellular localization of the autoimmune regulator protein. Characterization of nuclear targeting and transcriptional activation domain. J. Biol. Chem.276, 19597–19602 (2001).
   PubMed Web of Science ®Google Scholar
• Björses P, Halonen M, Palvimo JJ et al. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy–candidiasis– ectodermal dystrophy protein. Am. J. Hum. Genet.66, 378–392 (2000).
   PubMed Web of Science ®Google Scholar
• Pitkänen J, Doucas V, Sternsdorf T et al. The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein. J. Biol. Chem.275, 16802–16809 (2000).
   PubMed Web of Science ®Google Scholar
• Ramsey C, Bukrinsky A, Peltonen L. Systematic mutagenesis of the functional domains of AIRE reveals their role in intracellular targeting. Hum. Mol. Genet.11, 3299–3308 (2002).
   PubMed Web of Science ®Google Scholar
• Bottomley MJ, Collard MW, Huggenvik JI et al. The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation. Nat. Struct. Biol.8, 626–33 (2001).
   PubMedGoogle Scholar
• Söderbergh A, Rorsman F, Halonen M et al. Autoantibodies against aromatic l-amino acid decarboxylase identifies a subgroup of patients with Addison’s disease. J. Clin. Endocrinol. Metab.85, 460–463 (2000).
   Google Scholar
• Vaidya B, Imrie H, Geatch DR et al. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison’s disease. J. Clin. Endocrinol. Metab.85, 688–691 (2000).
   Google Scholar
• Bøe Wolff AS, Oftedal B, Johansson S et al.AIRE variations in Addison’s disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes Immun.9, 130–136 (2008).
   Google Scholar
• Ramsey C, Winqvist O, Puhakka L et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum. Mol. Genet.11, 397–409 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson MS, Venanzi ES, Klein L et al. Projection of an immunological self shadow within the thymus by the aire protein. Science298, 1395–1401 (2002).
   PubMed Web of Science ®Google Scholar
• Thomsen M, Platz P, Andersen OO et al. MLC typing in juvenile diabetes mellitus and idiopathic Addison’s disease. Transplant. Rev.22, 125–147 (1975).
   PubMedGoogle Scholar
• Eisenbarth G, Wilson P, Ward F, Lebovitz HE. HLA type and occurrence of disease in familial polyglandular failure. N. Engl. J. Med.298, 92–94 (1978).
   Google Scholar
• Eisenbarth GS, Wilson PW, Ward F, Buckley C, Lebovita H. The polyglandular failure syndrome: disease inheritance, HLA type, and immune function. Ann. Intern. Med.91, 528–533 (1979).
   PubMedGoogle Scholar
• Valenta LJ, Bull RW, Hackel E, Bottazzo GF. Correlation of the HLA-A1, B8 haplotypes with circulating autoantibodies in a family with increased incidence of autoimmune disease. Acta Endocrinol. (Copenh.)100, 143–149 (1982).
   Google Scholar
• Butler MG, Hodes ME, Conneally PM, Biegel AA, Wright JC. Linkage analysis in a large kindred with autosomal dominant transmission of polyglandular autoimmune disease type II (Schmidt syndrome). Am. J. Med. Genet.18, 61–65 (1984).
   Google Scholar
• Maclaren NK, Riley WJ. Inherited susceptibility to autoimmune Addison’s disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with type I autoimmune polyglandular syndrome. J. Clin. Endocrinol. Metab.62, 455–459 (1986).
   PubMed Web of Science ®Google Scholar
• Latinne D, Vandeput Y, De Bruyere M, Bottazzo F, Sokal G, Crabbe J. Addison’s disease: immunological aspects. Tissue Antigens30, 23–24 (1987).
   PubMedGoogle Scholar
• Boehm BO, Manfras B, Seidl S et al. The HLA-DQ β non-Asp-57 allele: a predictor of future insulin-dependent diabetes mellitus in patients with autoimmune Addison’s disease. Tissue Antigens37, 130–132 (1991).
   Google Scholar
• Weetman AP, Zhang L, Tandon N, Edwards OM. HLA associations with autoimmune Addison’s disease. Tissue Antigens38, 31–33 (1991).
   PubMed Web of Science ®Google Scholar
• Partanen J, Peterson P, Westman P, Aranko S, Krohn K. Major histocompatibility complex class II and III in Addison’s disease. MHC alleles do not predict autoantibody specificity and 21--hydroxylase gene polymorphism has no independent role in disease susceptibility. Hum. Immunol.41, 135–140 (1994).
   Google Scholar
• Badenhoop K, Walfish PG, Rau H et al. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J. Clin. Endocrinol. Metab.80, 2112–2117 (1995).
   PubMed Web of Science ®Google Scholar
• Betterle C, Volpato M, Rees Smith B et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. J. Clin. Endocrinol. Metab.82, 932–938 (1997).
   PubMedGoogle Scholar
• Yu L, Brewer KW, Gates S et al.DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison’s disease. J. Clin. Endocrinol. Metab.84, 328–335 (1999).
   PubMed Web of Science ®Google Scholar
• Gambelunghe G, Falorni A, Ghaderi M et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison’s disease. J.Clin. Endocrinol. Metab.84, 3701–3707 (1999).
   PubMed Web of Science ®Google Scholar
• Myhre AG, Undlien DE, Løvås K et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J. Clin. Endocrinol. Metab.87, 618–623 (2002).
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Meyer A, Tuschy U, Lohmann T. HLA-DQA1*0301-associated susceptibility for autoimmune polyglandular syndrome type II and III. Horm. Metab. Res.35, 120–124 (2003).
   PubMedGoogle Scholar
• Gambelunghe G, Kockum I, Bini V et al. Retrovirus-like long terminal repeat DQ-LTR13 and genetic susceptibility to type 1 diabetes mellitus and autoimmune Addison’s disease. Diabetes54, 900–905 (2005).
   PubMedGoogle Scholar
• Barker JM, Ide A, Hostetler C et al. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison’s disease in a high-risk population. J. Clin. Endocrinol. Metab.90, 128–134 (2005).
   PubMedGoogle Scholar
• Gombos Z, Hermann R, Kiviniemi M et al. Analysis of extended human leukocyte antigen haplotype association with Addison’s disease in three populations. Eur. J. Endocrinol.157, 757–761 (2007).
   Google Scholar
• Michelsen B, Lernmark Å. Molecular cloning of a polymorphic DNA endonuclease fragment associates insulin-dependent diabetes mellitus with HLA-DQ. J. Clin. Invest.79, 1144–1152 (1987).
   Google Scholar
• Chase K, Sargan D, Miller K, Ostrander EA, Lark KG. Understanding the genetics of autoimmune disease: two loci that regulate late onset Addison’s disease in Portuguese Water Dogs. Int. J. Immunogenet.33, 179–184 (2006).
   Google Scholar
• Rønningen KS, Keiding N, Green A, EURODIAB ACE Study Group. Correlations between the incidence of childhood-onset Type I diabetes in Europe and HLA genotypes. Diabetologia44(Suppl. 3), B51–B59 (2001).
   Web of Science ®Google Scholar
• Jackson R, McNicol AM, Farquharson M, Foulis AK. Class II MHC expression in normal adrenal cortex and cortical cells in autoimmune Addison’s disease. J. Pathol.155, 113–120 (1988).
   Google Scholar
• Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature409, 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Leib-Mösch C, Haltmeier M, Werner T et al. Genomic distribution and transcription of solitary HERV-K LTRs. Genomics18, 261–269 (1993).
   PubMed Web of Science ®Google Scholar
• Kambhu S, Falldorf P, Lee JS. Endogenous retroviral long terminal repeats within the HLA-DQ locus. Proc. Natl Acad. Sci. USA87, 4927–4931 (1990).
   PubMed Web of Science ®Google Scholar
• Donner H, Tönjes RR, Van der Auwera B et al. The presence or absence of a retroviral long terminal repeat influences the genetic risk for Type 1 diabetes conferred by human leukocyte antigen DQ haplotypes. J. Clin. Endocrinol. Metab.84, 1404–1408 (1999).
   PubMed Web of Science ®Google Scholar
• Pascual M, Martin J, Nieto A et al. Distribution of HERV-LTR elements in the 5´-flanking region of HLA-DQB1 and association with autoimmunity. Immunogenetics53, 114–118 (2001).
   PubMed Web of Science ®Google Scholar
• Pani MA, Seidl C, Bieda K et al. Preliminary evidence that an endogenous retroviral long-terminal repeat (LTR13) at the HLA-DQB1 gene locus confers susceptibility to Addison’s disease. Clin. Endocrinol. (Oxf.)56, 773–777 (2002).
   PubMedGoogle Scholar
• Donner H, Tönjes RR, Bontrop RE, Kurth R, Usadel KH, Badenhoop K. MHC diversity in Caucasians, investigated using highly heterogeneous noncoding sequence motifs at the DQB1 locus including a retroviral long terminal repeat element, and its comparison to nonhuman primate homologues. Immunogenetics51, 898–904 (2000).
   Google Scholar
• Bieda K, Pani MA, Van der Auwera B et al. A retroviral long terminal repeat adjacent to the HLA DQB1 gene (DQ-LTR13) modifies Type I diabetes susceptibility on high risk DQ haplotypes. Diabetologia45, 443–447 (2002).
   PubMedGoogle Scholar
• Krach K, Badenhoop K, Tönjes RR. The IDDM-associated solitary retroviral promoters DQ-LTR3 and DQ-LTR13 have a distinct impact on the expression of selected DQB1 genes in different cell lines in vitro.Immunogenetics55, 521–529 (2003).
   Google Scholar
• Reichstetter S, Krellner PH, Meenzen CM, Kalden JR, Wassmuth R. Comparative analysis of sequence variability in the upstream regulatory region of the HLA-DQB1 gene. Immunogenetics39, 207–212 (1994).
   Google Scholar
• Bahram S. Mizuki N, Inoko H, Spies T. Nucleotide sequence of a human MHC class I MICA gene. Immunogenetics44, 80–81 (1996).
   Google Scholar
• Bahram S. MIC genes: from genetics to biology. Adv. Immunol.76, 1–60 (2000).
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Co-stimulation of CDαβ T cells via engagement by MIC induced on virus-infected cells. Nat. Immun.2, 255–260 (2001).
   Google Scholar
• Yamamoto K, Fujiyama Y, Andoh A, Bamba T, Okabe H. Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line. Biochem. Biophys. Acta1526, 10–12 (2001).
   PubMed Web of Science ®Google Scholar
• Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science279, 1737–1740 (1998).
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumour associated expression and recognition by tumour-derived γδ T cells of MICA and MICB. Proc. Natl Acad. Sci. USA96, 6879–6884 (1999).
   PubMed Web of Science ®Google Scholar
• Zwirner NW, Fernandez-Miña MA, Stastny P. MICA, a new polymorphic HLA related antigen, is expressed mainly by keratinocytes, endothelial cells and monocytes. Immunogenetics47, 139–148 (1998).
   PubMed Web of Science ®Google Scholar
• Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl Acad. Sci. USA93, 12445–12450 (1996).
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science285, 727–729 (1999).
   PubMed Web of Science ®Google Scholar
• Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat. Immunol.2, 443–451 (2001).
   PubMed Web of Science ®Google Scholar
• Ota M, Katsuyama Y, Mizuki N et al. Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. Tissue Antigens49, 448–454 (1997).
   PubMedGoogle Scholar
• Fodil N, Laloux N, Wanner P et al. Allelic repertoire of the human MHC class I MICA gene. Immunogenetics44, 351–357 (1996).
   PubMedGoogle Scholar
• Ricci Vitiani L, Potolicchio I, D’Amato M, Baricordi OR, Sorrentino R. MICA exon 5 microsatellite typing by DNA heteroduplex analysis: a new polymorphism in the transmembrane region. Tissue Antigens51, 309–311 (1998).
   Google Scholar
• Perez-Rodriguez M, Corell A, Arguello JR et al. A new MICA allele with ten alanine residues in the exon 5 microsatellite. Tissue Antigens55, 162–165 (2000).
   Google Scholar
• Rueda B, Pascual M, López-Nevot MA, González E, Martín J. A new allele within the transmembrane region of the human MICA gene with seven GCT repeats. Tissue Antigens60, 526–528 (2002).
   Google Scholar
• Gambelunghe G, Brozzetti A, Ghaderi M, Tortoioli C, Falorni A. MICA8: a new allele within MHC class I chain-related A transmembrane region with eight GCT repeats. Hum. Immunol.67, 1005–1007 (2006).
   PubMedGoogle Scholar
• Park YS, Sanjeevi CB, Robles D et al. Additional association of intra-MHC genes, MICA and D6S273, with Addison’s disease. Tissue Antigens60, 155–163 (2002).
   PubMedGoogle Scholar
• LeibundGut-Landmann S, Waldburger JM, Krawczyk M et al. Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol.34, 1513–1525 (2004).
   PubMed Web of Science ®Google Scholar
• Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol. Cell. Biol.20, 6185–6194 (2000).
   PubMedGoogle Scholar
• Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell109, S21–S33 (2002).
   PubMed Web of Science ®Google Scholar
• Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS. Single nucleotide polymoprhisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA). Genes Immun.3, 34–37 (2002).
   Google Scholar
• Koizumi K, Okamoto H, Iikuni N et al. Single nucleotide polymoprhisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus. Ann. Rheum. Dis.64, 947–950 (2006).
   Google Scholar
• Swanberg M, Lidman O, Padyukov L et al.MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat. Genet.37, 486–494 (2005).
   PubMed Web of Science ®Google Scholar
• Rassmussen HB, Kelly MA, Clausen J. Genetic susceptibility to multiple sclerosis: detection of polymorphic nucleotides and an intron in the 3´ untranslated region of the major histocompatibility complex class II transactivator gene. Hum. Immunol.62, 371–377 (2001).
   Google Scholar
• Sartoris S, Brendolan A, Degola A et al. Analysis of CIITA encoding AIR-1 gene promoters in insulin-dependent diabetes mellitus and rheumatoid arthritis patients from the northeast of Italy: absence of sequence variability. Hum. Immunol.61, 599–604 (2000).
   Google Scholar
• Akkad DA, Jagiello P, Szyld P et al. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int. J. Immunogenet.33, 59–61 (2006).
   PubMedGoogle Scholar
• Yazdani-Biuki B, Brickmann K, Wohlfahrt K et al. The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients. Arthritis Res. Ther.8(4), R97 (2006).
   Google Scholar
• Linga-Reddy MV, Gunnarsson I, Svenungsson E et al. A polymorphic variant in the MHC2TA gene is not associated with systemic lupus erythematosus. Tissue Antigens70, 412–414 (2007).
   Google Scholar
• Ghaderi M, Gambelunghe G, Tortoioli C et al.MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J. Clin. Endocrinol. Metab.91, 4107–4111 (2006).
   PubMedGoogle Scholar
• Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunol.3, 1097–1101 (2002).
   PubMed Web of Science ®Google Scholar
• Vaidya B, Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur. J. Endocrinol.150, 619–626 (2004).
   PubMed Web of Science ®Google Scholar
• Donner H, Braun J, Seidl C et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto’s thyroiditis and Addison’s disease. J. Clin. Endocrinol. Metab.82, 4130–4132 (1997).
   PubMed Web of Science ®Google Scholar
• Kemp EH, Ajjan RA, Husebye ES et al. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison’s disease in English patients. Clin. Endocrinol.49, 609–613 (1998).
   PubMed Web of Science ®Google Scholar
• Pani MA, Seissler J, Usadel KH, Badenhoop K. Vitamin D receptor genotype is associated with Addison’s disease. Eur. J. Endocrinol.147, 635–640 (2002).
   Google Scholar
• Lopez ER, Zwermann O, Segni M et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison’s disease, Hashimoto’s thyroiditis, Graves’ disease and Type 1 diabetes mellitus in Germans. Eur. J. Endocrinol.151, 193–197 (2004).
   Google Scholar
• Smith MW, Carrington M, Winkler C et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science277, 959–965 (1997).
   PubMed Web of Science ®Google Scholar
• Horuk R. Chemokine receptors. Cytokine Growth Factor Rev.12, 313–335 (2001).
   PubMed Web of Science ®Google Scholar
• Gambelunghe G, Ghaderi M, Brozzetti A et al.CCR2-64I and CCR5-Δ32 are not associated with autoimmune Addison’s disease. Eur. J. Immunogenet.31, 73–76 (2004).
   Google Scholar
• Fischereder M, Luckow B, Hocher B et al. CC chemokine receptor 5 and renal-transplant survival. Lancet357, 1758–1761 (2001).
   PubMed Web of Science ®Google Scholar
• Garred P, Madsen HO, Petersen J et al. CC chemokine receptor 5 polymorphism in rheumatoid artrhritis. J. Rheumatol.25, 1462–1465 (1998).
   PubMed Web of Science ®Google Scholar
• Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. Association of CCR5 δ 32 with reduced risk of asthma. Lancet354, 1264–1265 (1999).
   PubMedGoogle Scholar
• Velaga MR, Wilson V, Jennings CE et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves’ disease. J. Clin. Endocrinol. Metab.89, 5862–5865 (2004).
   PubMed Web of Science ®Google Scholar
• Kahles H, Ramos-Lopez E, Lange B, Zwermann O, Reincke M, Badenhoop K. Sex-specific association of PTPN22 1858T with Type 1 diabetes but not with Hashimoto’s thyroiditis or Addison’s disease in the German population. Eur. J. Endocrinol.153, 895–899 (2005).
   PubMed Web of Science ®Google Scholar
• Skinningsrud B, Husebye ES, Gervin K et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison’s disease. Eur. J. Hum. Genet. DOI: 10.1038/ejhg.2008.33 (2008) (Epub ahead of print).
   Google Scholar